The diversification at Swedish Orphan Biovitrum AB (Sobi) continued Monday with its acquisition of Dova Pharmaceuticals Inc. in a deal worth about $915 million. Read More
Shares of Seattle Genetics Inc. (NASDAQ:SGEN) rose 12.4% to $85.40 on news that an antibody-drug conjugate (ADC) it is developing with Tokyo-based Astellas Pharma Inc., when combined with Keytruda (pembrolizumab, Merck & Co. Inc.), shrank tumors in the majority of people participating in a phase I first-line bladder cancer study. Read More
HONG KONG – GI Innovation Inc., a microbiome combination drug developer based in Seoul, South Korea, has recently issued fully paid convertible preferred stock (CPS) worth KRW37.5 billion (US$31 million) for a series B investment. Read More
BARCELONA, Spain – Sunday's Presidential Symposium at the 2019 Congress of the European Society of Medical Oncology was devoted to breast cancer studies, and two of those studies – MONARCH-2 and MONALEESA-3 – reported an overall survival (OS) benefit of combining a CDK4/6 inhibitor with endocrine therapy Faslodex (fulvestrant) in metastatic hormone receptor-positive (HR+) breast cancer in several different settings. Read More
BARCELONA, Spain – At the 2019 Conference of the European Society of Medical Oncology (ESMO), results from the ClarIDHy and FIGHT-202 trials, both testing drugs for the treatment of cholangiocarcinoma, illustrated how molecular medicine can bring new treatments to rare tumors. Read More
HONG KONG –South Korea's leading biopharmaceutical developer, Celltrion Inc., has launched its early/metastatic breast and gastric cancer biosimilar Herzuma (trastuzumab) in Iraq. It is Herzuma's first foray into the Middle Eastern region. Read More
CK Hutchison Holdings Ltd., of London, said it intends to sell approximately 1.3% of the total outstanding share capital in Hutchison China Meditech Ltd., of Hong Kong, through an underwritten public offering, which would reduce its stake in the company from 51.1% to 49.9%. Read More
Three reports the Health and Human Services Office of Inspector General (OIG) released last week highlighting concerns about NIH oversight of taxpayer-funded research and the increasing threats of intellectual property theft by foreign governments are raising flags with U.S. lawmakers. Read More
Vir Biotechnology Inc., of San Francisco, has established terms for its proposed IPO, planning to offer 7.14 million shares in the price range of $20 to $22. Read More
Wall Street will have to wait until the American Heart Association (AHA) meeting next month in Philadelphia for full data from Resverlogix Inc.'s phase III BETonMACE trial with apabetalone, but disclosure of the endpoint miss was enough to send investors fleeing. Read More
